DUBLIN – Shares in Neovacs SA surged by as much as 35 percent Tuesday on news of an option agreement in China worth up to €65 million (US$68.5 million) in up-front and milestone payments for its therapeutic vaccine, IFNα Kinoid, which is currently undergoing a phase IIb trial in lupus. The deal, with Biosense Global LLC, covers Macao, Hong Kong, Taiwan and Singapore, as well as China.